Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGCTX5)

Drug Name
Combined PR1/WT1 vaccine Drug Info
Synonyms Combined PR1/WT1 vaccine (leukemia); Combined PR1/WT1 vaccine (leukemia), NIH; Proteinase 1/Wilms tumor 1 vaccine (leukemia), NIH
Indication
Disease Entry ICD 11 Status REF
Myeloid leukaemia 2B33.1 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMGCTX5

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Leukocyte proteinase-3 (PRTN3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tiprelestat DM1SB94 Myocardial infarction BA41-BA43 Phase 2 [3]
PMID22595175C4g DM9SLUK Discovery agent N.A. Investigative [4]
Drug(s) Targeting Wilms tumor protein (WT1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
WT1 peptide vaccine DMZ67Q0 leukaemia 2A60-2B33 Phase 2 [5]
WT1-targeted autologous dendritic cell vaccine DMNFZYE Acute myeloid leukaemia 2A60 Phase 2 [6]
FPI-01 DMXOTMP Acute myeloid leukaemia 2A60 Phase 2 [7]
WT-4869 DM3FIMD leukaemia 2A60-2B33 Phase 1/2 [8]
GSK-2130579A DMRXW9P Acute myeloid leukaemia 2A60 Phase 1 [9]
INNO-305 DMG6S8U Acute myeloid leukaemia 2A60 Phase 1 [10]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukocyte proteinase-3 (PRTN3) TT5MLC4 PRTN3_HUMAN Not Available [2]
Wilms tumor protein (WT1) TTZ8UT4 WT1_HUMAN Not Available [2]

References

1 Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies. Front Immunol. 2015 Feb 4;6:36.
2 Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008 Jan 1;111(1):236-42.
3 Company report (Proteo Biotech AG)
4 N-Acyl and N-sulfonyloxazolidine-2,4-diones are pseudo-irreversible inhibitors of serine proteases. Bioorg Med Chem Lett. 2012 Jun 15;22(12):3993-7.
5 Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3beta sequence associated with remission in one patient is detectable in other vaccinated patients. Cancer ImmunolImmunother. 2012 Mar;61(3):313-22.
6 ClinicalTrials.gov (NCT01686334) Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission. U.S. National Institutes of Health.
7 Clinical pipeline report, company report or official report of Formula Pharmaceuticals.
8 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033385)
9 Spoilight on personalized medicine. A pharma matters report, Thomson Reuters, 2012.
10 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023753)